• About us
• Contact

Advertisement

Organisation › Details

AmpTec GmbH

AmpTec is an internationally leading provider of RNA technology products, including RNA isolation and mRNA amplification kits, synthetic long RNAs and DNAs as well as functional mRNAs. We are committed to direct and flexible customer interactions with life science industries and academic research institutions around the world, including on-site technical support. *

 

	Start	2005-06-01 splitoff
	Group	Merck (DE) (Group)
	Predecessor	artus Gesellschaft für molekularbiologische Diagnostik und Entwicklung mbH
	Industry	PCR technology
	Industry 2	ExpressArt RNA amplification kit
	Person	Krupp, Guido (AmpTec 200810 Managing Director before artus)
	Person 2	Scheinert, Peter (AmpTec GmbH 201201 Managing Director)
	Region	Hamburg
	Country	Germany
	Street	4A Königstr.
	City	22767 Hamburg
	Tel	+49-40-636747-22
		Address record changed: 2021-01-11
Basic data	Employees	B: 11 to 50 (2021-01-07)
		�About Section� taken from web site of organisation on 07.01.
		Record changed: 2023-12-30

Advertisement

More documents for Merck (DE) (Group)

• [1] Caris Life Sciences Inc.. (4/4/24). "Press Release: Caris Life Sciences Announces Partnership with Merck KGaA, Darmstadt, Germany to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development". Irving, TX....
• [2] BioGeneration Ventures B.V.. (4/2/24). "Press Release: BGV Appoints Peter Halle, PhD as Venture Partner". Amsterdam....
• [3] C4 Therapeutics, Inc.. (3/4/24). "Press Release: C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins". Watertown, MA....
• [4] ITM Isotope Technologies Munich SE. (12/14/23). "Press Release: ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics". Garching....
• [5] Merck KGaA. (12/4/23). "Press Release: Merck Strengthens Oncology Portfolio through Commercialization Agreement With Abbisko for Phase III Asset, Pimicotinib [Not intended for UK-, US- or Canada-based media]". Darmstadt....
• [6] Merck KGaA. (11/21/23). "Press Release: Merck Expands Newest Biologics Testing Center in Shanghai". Shanghai....
• [7] Merck KGaA. (11/14/23). "Press Release: Merck Announces Plans for New U.S. Healthcare Headquarters in Boston’s Seaport District [Not intended for US-based media]". Darmstadt....
• [8] Merck KGaA. (10/30/23). "Press Release: Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate [Not intended for US-, Canada- or UK-based media]". Darmstadt...
• [9] Exscientia plc. (10/3/23). "Press Release: Exscientia Details Pipeline Prioritisation Strategy". Oxford....
• [10] BenevolentAI. (9/20/23). "Press Release: BenevolentAI Signs Strategic Collaboration with Merck". London....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.